PF 4995274

Drug Profile

PF 4995274

Alternative Names: PF-04995274; PF-4995274

Latest Information Update: 30 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Pfizer; University of Oxford
  • Class Antidementias
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Depressive disorders
  • Discontinued Alzheimer's disease

Most Recent Events

  • 16 May 2018 Phase-I clinical trials in Depressive disorders in United Kingdom (PO) (NCT03516604)
  • 04 May 2018 Pfizer plans the RESTAND phase I trial for Depression in United Kingdom (NCT03516604)
  • 04 May 2018 University of Oxford plans the RESTART phase I trial for Depression in United Kingdom , (NCT03515733)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top